查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933356

全球兒童疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

Pediatric Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 請詢問到貨日

價格

兒童疫苗市場成長因素

2025年全球兒童疫苗市場規模達到468.6億美元，預計2026年將成長至504.6億美元，到2034年將達到1214.6億美元，預測期內年複合成長率（CAGR）為11.61%。北美地區將憑藉先進的醫療基礎設施、強有力的政府支持和完善的免疫接種計劃，在2025年佔據市場主導地位，市場佔有率為51.84%。兒童疫苗在預防兒童危及生命的疾病方面發揮著非常重要的作用，這些疾病包括瘧疾、小兒麻痺、肺炎鏈球菌感染、麻疹和腮腺炎。各國政府和國際組織加大投資，包括蓋茲基金會承諾在2025年向全球疫苗免疫聯盟（Gavi）提供16億美元的資金，加強全球免疫規劃。

市場動態

市場驅動因素：市場主要受政府支持和大規模免疫規劃的擴展所驅動。全球疫苗免疫聯盟（Gavi）和聯合國兒童基金會（UNICEF）等國際組織與各國政府合作進行疫苗採購和免疫接種計畫。例如，2025年1月，聯合國兒童基金會向17個瘧疾流行非洲國家的兒童提供了超過980萬劑瘧疾疫苗，以支持常規免疫規劃。這些努力提高疫苗的可及性、覆蓋率和需求。

阻礙因素：疫苗猶豫仍然是主要的阻礙因素，尤其是在中低收入國家。對安全性的擔憂、錯誤訊息以及對醫療衛生系統的不信任阻礙了疫苗的接種。世界衛生組織（WHO）於2019年將疫苗猶豫列為全球十大健康威脅之一，而新冠疫情進一步加劇了這種猶豫情緒。

機會：不斷增加的研發投入帶來了巨大的成長機會。目前，針對腸毒素性大腸桿菌（ETEC）和拉沙熱等高傳染性疾病的疫苗需求尚未被滿足。例如，美國國立衛生研究院（NIH）在2024年報告指出，拉沙熱每年在西非造成約 5000 人死亡，凸顯了對新型疫苗的潛在需求。

挑戰：缺乏冷藏基礎設施是一項重大挑戰。儲存不當和冷鏈中斷會導致疫苗浪費和效力降低。2021年，約有27億人因缺乏冷鏈物流而無法可靠地獲得疫苗，凸顯了建立可靠的儲存系統以支持免疫規劃的必要性。

市場趨勢

結合疫苗正成為一大趨勢，簡化了免疫接種程序，並有助於提高疫苗覆蓋率。2025年7月，全球疫苗免疫聯盟（Gavi）在茅利塔尼亞和塞內加爾推出了六價疫苗，可預防六種疾病：白喉、破傷風、百日咳、乙型肝炎、第二型流感嗜血桿菌（Hib）和小兒麻痺。結合疫苗有助於降低成本，並提高大規模疫苗接種活動的依從性。

細分市場分析

依類型劃分：重組疫苗、結合疫苗和次單位疫苗領域因其廣泛的適用性和高效性而佔據領先地位。Merck公司與聯合國兒童基金會合作建立伊波拉疫苗儲備就是一個具有良好成長前景的例子。廣泛用於對抗麻疹、腮腺炎和呼吸道合胞病毒（RSV）的減毒活疫苗也不斷擴大，例如Codagenix公司於2023年進行的兒童CodaVax-RSV臨床試驗。滅活疫苗，例如印度的Covaxin和Corbevax，因其穩定性提高而備受關注。 mRNA疫苗，例如Moderna公司兒童的Spikevax，由於其可擴展性和監管批准的優勢，預計將快速成長。

依疾病分類：病毒性疾病佔市場主導地位，這主要受麻疹、腮腺炎、德國麻疹、人類乳突病毒（HPV）、流感和小兒麻痺等疾病高感染率的驅動。細菌疫苗，例如雅培公司用於預防肺炎球菌感染的PneumoShield 14疫苗，也呈現出顯著的成長動能。

依給藥途徑：口服疫苗因其給藥方便而佔據市場主導地位，支持大規模免疫接種計劃，例如巴布亞新幾內亞的OPV3疫苗覆蓋率，到2024年達到44%。注射疫苗由於能夠提供全身免疫和長期保護，預計將穩定成長。

依通路：政府供應商透過與實施大規模免疫接種運動的組織合作，主導市場。例如，Panacea Biotech公司在2020年向聯合國兒童基金會提供了4,000萬劑口服小兒麻痺疫苗，價值520萬美元。醫院和零售藥局由於疫苗的可及性和策略性合作夥伴關係（例如加拿大Wholehealth Pharmacy的Dose4Dose活動）而實現了成長。

區域展望

北美：2025年市場規模為209.4億美元，預計2026年將達229億美元。強大的基礎設施、研發實力和合作是推動成長的主要動力。美國在該地區佔據最大佔有率，這主要得益於Pfizer公司嬰兒呼吸道合胞病毒疫苗ABRYSVO等疫苗的批准。

歐洲：高疫苗接種覆蓋率和政府計畫是其佔有較大佔有率的重要因素。2023年核准的呼吸道合胞病毒疫苗ABRISVO等監管部門的核准，有助於緩解疫苗供應短缺問題。

亞太地區：由於麻疹等傳染病的高發生率，該地區是成長最快的市場。全球疫苗免疫聯盟（Gavi）預測，2025年東亞地區爆發大規模麻疹疫情，推動疫苗需求。

拉丁美洲、中東和非洲：由於疫苗接種計劃和世衛組織計畫（例如，目的是到2023年使非洲 500 多萬兒童獲得基本免疫恢復計劃），該地區佔據了很大佔有率。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家和地區的監管環境
  • 主要國家和地區的疫苗接種覆蓋率
  • 主要國家和地區的政府兒童免疫計劃
  • 兒科疫苗市場的技術進步
  • 主要產業趨勢：併購、商業合作等。

第5章 全球兒童疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依類型劃分
    • 減毒活疫苗
    • 滅活疫苗
    • 重組/結合/次單位疫苗
    • mRNA疫苗
    • 病毒載體疫苗
    • 類毒素
    • 其他
  • 市場分析、洞察與預測：依疾病劃分
    • 病毒性疾病
      • 甲型肝炎
      • 肝炎B
      • 小兒麻痺
      • 呼吸道合胞病毒（RSV）
      • 流感
      • 人類乳突病毒（HPV）
      • 麻疹、腮腺炎、德國麻疹（MMR）
      • 輪狀病毒
      • 帶狀皰疹
      • 其他
    • 細菌性疾病
      • 肺炎鏈球菌感染
      • 百白破疫苗（DTP）
      • 腦膜炎雙球菌感染
      • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依通路
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區
    • 北部美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美兒童疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲兒童疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞半島
    • 歐洲其他地區

第8章 亞太地區兒童疫苗市場分析市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲兒童疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第10章 中東與非洲兒童疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家/地區
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Merck &Co., Inc.
    • Sanofi.
    • Bharat Biotech.
    • GSK plc.
    • SINOVAC
    • Serum Institute of India Pvt. Ltd.
    • HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
    • Panacea Biotec
    • Bio Farma
    • AJ Vaccines A/S
    • Beijing Institute of Biological Products Co., Ltd.
Product Code: FBI113756

Growth Factors of pediatric vaccines Market

The global pediatric vaccines market was valued at USD 46.86 billion in 2025 and is projected to grow to USD 50.46 billion in 2026, reaching USD 121.46 billion by 2034, with a CAGR of 11.61% during the forecast period. North America dominated the market in 2025 with a share of 51.84%, driven by advanced healthcare infrastructure, strong government support, and robust vaccination programs. Pediatric vaccines play a critical role in preventing life-threatening diseases in children, including malaria, polio, pneumococcal infections, measles, mumps, and others. Increasing investments from governments and international organizations, such as the Gates Foundation's USD 1.6 billion support to Gavi in 2025, have bolstered vaccination programs worldwide.

Market Dynamics

Drivers: The market is primarily driven by government support and the expansion of mass vaccination programs. International organizations like Gavi and UNICEF are collaborating with governments for vaccine procurement and immunization initiatives. For example, in January 2025, UNICEF delivered over 9.8 million doses of malaria vaccines to children in 17 endemic African countries, supporting routine immunization programs. Such efforts increase vaccine accessibility, coverage, and demand.

Restraints: Vaccine hesitancy remains a major restraint, particularly in low- and middle-income countries. Safety concerns, myths, misinformation, and mistrust in healthcare systems have hampered adoption. WHO recognized vaccine hesitancy as a top ten global health threat in 2019, and the pandemic has further exacerbated reluctance.

Opportunities: Increasing research and development initiatives provide significant growth opportunities. There is an unmet need for vaccines against highly contagious diseases such as Enterotoxigenic Escherichia coli (ETEC) and Lassa fever. For instance, NIH reported in 2024 that Lassa fever causes approximately 5,000 deaths annually in West Africa, highlighting potential demand for novel vaccines.

Challenges: The lack of cold storage infrastructure poses significant challenges. Improper storage or breaks in the cold chain can lead to vaccine wastage and loss of potency. In 2021, around 2.7 billion people lacked dependable access to vaccines due to insufficient cold chain logistics, underscoring the need for reliable storage systems to support immunization programs.

Market Trends

Combination vaccines are emerging as a key trend, simplifying immunization schedules and increasing coverage. In July 2025, Gavi launched a hexavalent vaccine in Mauritania and Senegal, protecting against six diseases, including diphtheria, tetanus, pertussis, hepatitis B, Hib, and poliomyelitis. Combination vaccines reduce costs and improve compliance in mass vaccination campaigns.

Segmentation Analysis

By Type: The recombinant/conjugate/subunit vaccines segment dominates due to broad applications and high efficiency. Collaborations like Merck and UNICEF's Ebola vaccine stockpile highlight growth potential. Live attenuated vaccines, widely used against measles, mumps, and RSV, are also expanding, exemplified by Codagenix's CodaVax-RSV pediatric trial in 2023. Inactivated vaccines, such as India's Covaxin and Corbevax, are gaining traction due to enhanced stability. mRNA vaccines, including Moderna's Spikevax for children, are expected to grow rapidly due to scalability and regulatory approvals.

By Disease Indication: The viral diseases segment dominates, driven by high prevalence of measles, mumps, rubella, HPV, influenza, and polio. Bacterial vaccines, including Abbott's PneumoShield 14 for pneumococcal infections, are also witnessing significant growth.

By Route of Administration: Oral vaccines lead the market due to ease of administration, supporting mass immunization programs such as the OPV3 coverage of 44% in Papua New Guinea in 2024. Parenteral vaccines are expected to grow steadily, offering systemic immunity and long-term protection.

By Distribution Channel: Government suppliers dominate due to collaborations with operational entities for large-scale immunization campaigns. For example, Panacea Biotec supplied 40 million oral polio doses to UNICEF in 2020, valued at USD 5.2 million. Hospital and retail pharmacies are growing due to accessibility and strategic partnerships, such as Wholehealth Pharmacy's Dose4Dose campaign in Canada.

Regional Outlook

North America: Valued at USD 20.94 billion in 2025, projected to reach USD 22.9 billion in 2026, with strong infrastructure, R&D, and collaborations driving growth. The U.S. holds the largest regional share due to vaccine approvals like Pfizer's ABRYSVO for RSV in infants.

Europe: Substantial share driven by high immunization coverage and government programs. Regulatory approvals, such as Abrysvo for RSV in 2023, help close the vaccine supply gap.

Asia Pacific: Fastest-growing region due to high prevalence of infectious diseases like measles. Gavi reported significant measles outbreaks in East Asia in 2025, boosting vaccine demand.

Latin America & Middle East & Africa: Substantial share supported by vaccination initiatives and WHO programs, such as the Essential Immunization Recovery Plan vaccinating over 5 million children in Africa in 2023.

Competitive Landscape

The market is consolidated, with key players including Sanofi, Merck & Co., Inc., GSK plc., Bharat Biotech, Panacea Biotec, Serum Institute of India, SINOVAC, Haffkine Bio-Pharmaceutical, Bio Farma, AJ Vaccines, and Beijing Institute of Biological Products. Companies focus on new product launches, collaborations, and capacity expansion. For instance, Bharat Biotech collaborated with Bilthoven Biologicals in 2024 to strengthen oral polio vaccine production.

Conclusion

The global pediatric vaccines market is set to grow from USD 46.86 billion in 2025 to USD 50.46 billion in 2026, reaching USD 121.46 billion by 2034 at a CAGR of 11.61%. Growth is driven by government support, mass vaccination programs, R&D initiatives, combination vaccines, and strategic collaborations. North America dominates, while Asia Pacific emerges as the fastest-growing region. Despite challenges like cold chain limitations and vaccine hesitancy, expanding coverage and innovative products will propel the market forward.

Segmentation By Type

  • Live Attenuated
  • Inactivated
  • Recombinant/Conjugate/Subunit
  • mRNA Vaccine
  • Viral Vectors Vaccines
  • Toxoid
  • Others

By Disease Indication

  • Viral Diseases
    • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Polio
    • RSV
    • Influenza
    • HPV
    • Measles/Mumps/Rubella
    • Rotavirus
    • Shingles (Herpes Zoster)
    • Others
  • Bacterial Diseases
    • Pneumococcal Diseases
    • DTP
    • Meningococcal Diseases
    • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Children- By Key Countries/ Regions
  • 4.4. Technological Advancements in Pediatric Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Live Attenuated
    • 5.1.2. Inactivated
    • 5.1.3. Recombinant/Conjugate/Subunit
    • 5.1.4. mRNA Vaccine
    • 5.1.5. Viral Vectors Vaccines
    • 5.1.6. Toxoid
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Viral Diseases
      • 5.2.1.1. Hepatitis A
      • 5.2.1.2. Hepatitis B
      • 5.2.1.3. Polio
      • 5.2.1.4. RSV
      • 5.2.1.5. Influenza
      • 5.2.1.6. HPV
      • 5.2.1.7. MMR
      • 5.2.1.8. Rotavirus
      • 5.2.1.9. Shingles
      • 5.2.1.10. Others
    • 5.2.2. Bacterial Diseases
      • 5.2.2.1. Pneumococcal Diseases
      • 5.2.2.2. DTP
      • 5.2.2.3. Meningococcal Diseases
      • 5.2.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Live Attenuated
    • 6.1.2. Inactivated
    • 6.1.3. Recombinant/Conjugate/Subunit
    • 6.1.4. mRNA Vaccine
    • 6.1.5. Viral Vectors Vaccines
    • 6.1.6. Toxoid
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Viral Diseases
      • 6.2.1.1. Hepatitis A
      • 6.2.1.2. Hepatitis B
      • 6.2.1.3. Polio
      • 6.2.1.4. RSV
      • 6.2.1.5. Influenza
      • 6.2.1.6. HPV
      • 6.2.1.7. MMR
      • 6.2.1.8. Rotavirus
      • 6.2.1.9. Shingles
      • 6.2.1.10. Others
    • 6.2.2. Bacterial Diseases
      • 6.2.2.1. Pneumococcal Diseases
      • 6.2.2.2. DTP
      • 6.2.2.3. Meningococcal Diseases
      • 6.2.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Live Attenuated
    • 7.1.2. Inactivated
    • 7.1.3. Recombinant/Conjugate/Subunit
    • 7.1.4. mRNA Vaccine
    • 7.1.5. Viral Vectors Vaccines
    • 7.1.6. Toxoid
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Viral Diseases
      • 7.2.1.1. Hepatitis A
      • 7.2.1.2. Hepatitis B
      • 7.2.1.3. Polio
      • 7.2.1.4. RSV
      • 7.2.1.5. Influenza
      • 7.2.1.6. HPV
      • 7.2.1.7. MMR
      • 7.2.1.8. Rotavirus
      • 7.2.1.9. Shingles
      • 7.2.1.10. Others
    • 7.2.2. Bacterial Diseases
      • 7.2.2.1. Pneumococcal Diseases
      • 7.2.2.2. DTP
      • 7.2.2.3. Meningococcal Diseases
      • 7.2.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Live Attenuated
    • 8.1.2. Inactivated
    • 8.1.3. Recombinant/Conjugate/Subunit
    • 8.1.4. mRNA Vaccine
    • 8.1.5. Viral Vectors Vaccines
    • 8.1.6. Toxoid
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Viral Diseases
      • 8.2.1.1. Hepatitis A
      • 8.2.1.2. Hepatitis B
      • 8.2.1.3. Polio
      • 8.2.1.4. RSV
      • 8.2.1.5. Influenza
      • 8.2.1.6. HPV
      • 8.2.1.7. MMR
      • 8.2.1.8. Rotavirus
      • 8.2.1.9. Shingles
      • 8.2.1.10. Others
    • 8.2.2. Bacterial Diseases
      • 8.2.2.1. Pneumococcal Diseases
      • 8.2.2.2. DTP
      • 8.2.2.3. Meningococcal Diseases
      • 8.2.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Live Attenuated
    • 9.1.2. Inactivated
    • 9.1.3. Recombinant/Conjugate/Subunit
    • 9.1.4. mRNA Vaccine
    • 9.1.5. Viral Vectors Vaccines
    • 9.1.6. Toxoid
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Viral Diseases
      • 9.2.1.1. Hepatitis A
      • 9.2.1.2. Hepatitis B
      • 9.2.1.3. Polio
      • 9.2.1.4. RSV
      • 9.2.1.5. Influenza
      • 9.2.1.6. HPV
      • 9.2.1.7. MMR
      • 9.2.1.8. Rotavirus
      • 9.2.1.9. Shingles
      • 9.2.1.10. Others
    • 9.2.2. Bacterial Diseases
      • 9.2.2.1. Pneumococcal Diseases
      • 9.2.2.2. DTP
      • 9.2.2.3. Meningococcal Diseases
      • 9.2.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Pediatric Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Live Attenuated
    • 10.1.2. Inactivated
    • 10.1.3. Recombinant/Conjugate/Subunit
    • 10.1.4. mRNA Vaccine
    • 10.1.5. Viral Vectors Vaccines
    • 10.1.6. Toxoid
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Viral Diseases
      • 10.2.1.1. Hepatitis A
      • 10.2.1.2. Hepatitis B
      • 10.2.1.3. Polio
      • 10.2.1.4. RSV
      • 10.2.1.5. Influenza
      • 10.2.1.6. HPV
      • 10.2.1.7. MMR
      • 10.2.1.8. Rotavirus
      • 10.2.1.9. Shingles
      • 10.2.1.10. Others
    • 10.2.2. Bacterial Diseases
      • 10.2.2.1. Pneumococcal Diseases
      • 10.2.2.2. DTP
      • 10.2.2.3. Meningococcal Diseases
      • 10.2.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co., Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bharat Biotech.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. GSK plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. SINOVAC
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Serum Institute of India Pvt. Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Panacea Biotec
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bio Farma
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. AJ Vaccines A/S
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Beijing Institute of Biological Products Co., Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 2: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 3: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 4: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 5: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 6: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 7: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 8: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 9: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 10: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 11: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 12: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 13: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 14: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 15: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 16: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 17: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 18: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 19: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 21: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 23: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 24: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 25: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 26: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 27: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 28: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 30: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 31: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 32: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 33: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 34: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 35: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 37: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2021-2034
  • Table 38: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2021-2034
  • Table 39: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2021-2034
  • Table 40: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 41: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 42: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Pediatric Vaccines Market Revenue Breakdown (USD billion, %), By Region, 2025 & 2034
  • Figure 2: Global Pediatric Vaccines Market Value Share (%), By Type, 2025 & 2034
  • Figure 3: Global Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025 & 2034
  • Figure 4: Global Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 5: Global Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 6: Global Pediatric Vaccines Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 8: North America Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 9: North America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 10: North America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 11: North America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 12: North America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 13: North America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 14: North America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 15: North America Pediatric Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Pediatric Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 18: Europe Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 19: Europe Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 20: Europe Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 21: Europe Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 22: Europe Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 23: Europe Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 24: Europe Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 25: Europe Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 28: Asia Pacific Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 29: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 30: Asia Pacific Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 31: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 33: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 38: Latin America Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 39: Latin America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 40: Latin America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 41: Latin America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 42: Latin America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 43: Latin America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 45: Latin America Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 48: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Type, 2025
  • Figure 49: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2025 & 2034
  • Figure 50: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Disease Indication, 2025
  • Figure 51: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Route of Administration, 2025
  • Figure 53: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 55: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Pediatric Vaccines Market Share (%), By Company, 2025